

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5883456

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MICHAEL P. LISANTI	06/25/2018
FEDERICA SOTGIA	06/25/2018
RECEIVING PARTY DATA	
Name:	LUNELLA BIOTECH, INC.
Street Address:	145 RICHMOND ROAD
City:	OTTAWA
State/Country:	ONTARIO
Postal Code:	K1Z 1A1
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16626426
CORRESPONDENCE DATA	
Fax Number:	(703)816-4100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	703-816-4000
Email:	PTOMAIL@nixonvan.com
Correspondent Name:	NIXON & VANDERHYE, PC
Address Line 1:	901 NORTH GLEBE ROAD, 11TH FLOOR
Address Line 4:	ARLINGTON, VIRGINIA 22203
ATTORNEY DOCKET NUMBER:	JBB-6814-144
NAME OF SUBMITTER:	JOSHUA B. BRADY
SIGNATURE:	/Joshua B. Brady/
DATE SIGNED:	12/24/2019
This document serves as an Oath/Declaration (37 CFR 1.63).	
Total Attachments: 2	
source=6814-144_DECLARATION_ASSIGNMENT_Mitoketoscins_DnA-PCT#page1.tif	
source=6814-144_DECLARATION_ASSIGNMENT_Mitoketoscins_DnA-PCT#page2.tif	

Doc code: Oath
Document Description: Oath or declaration filed

Attorney Docket Number	JBS-6314-32
First Named Inventor	LISANTI, Michael P.

**INVENTOR'S DECLARATION AND ASSIGNMENT FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

- Declaration Submitted With Initial Filing
OR
 Declaration Submitted After Initial Filing (surcharge (37 C.F.R. § 1.16(f)) required)

**MITOKETOSCINS: MITOCHONDRIAL-BASED THERAPEUTICS TARGETING
KETONE METABOLISM IN CANCER CELLS**

(Title of the Invention)

As a below named inventor, I hereby declare that:

This declaration is directed to:

- the attached application, or
 United States Application Number _____ filed _____, or
 PCT International application number PCT/US2018/39954 filed on June 25, 2018.

The above-identified application was made or authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WHEREAS, the undersigned (hereinafter ASSIGNOR), has made an invention in the Application identified above.

WHEREAS, LUNELLA BIOTECH, INC. (hereinafter ASSIGNEE), an entity, having an office and place of business at 8115 Maple Lawn Boulevard, #250 (32A), Fulton, MD 20759 UNITED STATES, and 145 Richmond Road, Ottawa, Ontario K1Z 1A1 (Canada), is desirous of acquiring an interest therein;

NOW, THEREFORE, in consideration of ASSIGNOR'S agreement with ASSIGNEE and/or other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the said ASSIGNOR by these presents hereby sells, assigns, and transfers unto the said ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR'S entire right, title and interest in the United States of America and all foreign countries, in and to the invention as described in the aforesaid application, and to the said application and to all subsequent applications based thereon including any and all continuations, divisions, reissues, and substitutes of said application, and all resulting patents, together with the right of priority under the International Convention for the Protection of Industrial Property, Inter-American Convention Relating to Patents, Designs and Industrial Models, and any other international agreements to which the United States of America adheres, and the ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE, for its interest as ASSIGNEE, its successors, assigns, and legal representatives. It is understood and agreed that ASSIGNEE'S attorneys Nixon & Vanderhye P.C. have represented only ASSIGNEE and will continue to represent only ASSIGNEE with respect to this invention;

ASSIGNOR hereby agrees to transfer a like interest upon request of said ASSIGNEE, its successors, assigns, and legal representatives, and without further remuneration, in and to any improvements, and applications for patents based thereon, growing out of or related to the said invention;

ASSIGNOR hereby agrees to execute any papers by ASSIGNEE, its successors, assigns, and legal representatives, deemed essential to ASSIGNEE'S full protection and title in and to the invention hereby transferred; and


ASSIGNOR hereby agrees, upon request of ASSIGNEE, and without further remuneration, to execute any and all papers desired by ASSIGNEE, for the filing and granting of foreign applications and the perfecting of title thereto in ASSIGNEE.

AGREED and executed as noted below:

Legal Name of Additional Joint Inventor, if any:
(E.g., Given Name (first and middle (if any)) and Family Name or Surname)

Michael P. Lisanti

Inventor's Signature:



Date:

June 25, 2018

Accepted by assignee Lunella Biotech, Inc.:  dated June 25, 2018
Michael P. Lisanti, as President of Lunella Biotech, Inc.

I/We acknowledge the duty to disclose information which is material to the patentability of this application as defined in 37 CFR §1.56.

PATENT

REEL: 051416 FRAME: 0178

Attorney Docket Number	JBB-6814-32
First Named Inventor	LISANTI, Michael P.

**INVENTOR'S DECLARATION AND ASSIGNMENT FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

- Declaration Submitted With Initial Filing
OR
 Declaration Submitted After Initial Filing (surcharge (37 C.F.R. § 1.16(f)) required)

**MITOKETOSCINS: MITOCHONDRIAL-BASED THERAPEUTICS TARGETING KETONE
METABOLISM IN CANCER CELLS**
(Title of the Invention)

As a below named inventor, I hereby declare that:

- This declaration is directed to:
 the attached application, or
 United States Application Number _____ filed _____, or
 PCT International application number PCT/US2018/39364 filed on June 25, 2018.

The above-identified application was made or authorized to be made by me.
 I believe I am the original inventor or an original joint inventor of a claimed invention in the application.
 I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WHEREAS, the undersigned (hereinafter ASSIGNOR), has made an invention in the Application identified above.
 WHEREAS, LUNELLA BIOTECH, INC. (hereinafter ASSIGNEE), an entity, having an office and place of business at 8115 Maple Lawn Boulevard, #255 (324), Fulton, MD 20759 UNITED STATES, and 149 Richmond Road, Ottawa, Ontario K1Z 1A1 (Canada), is desirous of acquiring an interest therein;

NOW, THEREFORE, in consideration of ASSIGNOR'S agreement with ASSIGNEE and/or other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the said ASSIGNOR by these presents hereby sells, assigns, and transfers unto the said ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR'S entire right, title and interest in the United States of America and all foreign countries, in and to the invention as described in the aforesaid application, and to the said application and to all subsequent applications based thereon including any and all continuations, divisions, reissues, and substitutes of said application, and all resulting patents, together with the right of priority under the International Convention for the Protection of Industrial Property, Inter-American Convention Relating to Patents, Designs and Industrial Models, and any other international agreements to which the United States of America adheres, and the ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE, for its interest as ASSIGNEE, its successors, assigns, and legal representatives. It is understood and agreed that ASSIGNEE'S attorneys Nixon & Vanderhye P.C. have represented only ASSIGNEE and will continue to represent only ASSIGNEE with respect to this invention;

ASSIGNOR hereby agrees to transfer a like interest upon request of said ASSIGNEE, its successors, assigns, and legal representatives, and without further remuneration, in and to any improvements, and applications for patents based thereon, growing out of or related to the said invention;

ASSIGNOR hereby agrees to execute any papers by ASSIGNEE, its successors, assigns, and legal representatives, deemed essential to ASSIGNEE'S full protection and title in and to the invention hereby transferred, and

ASSIGNOR hereby agrees, upon request of ASSIGNEE, and without further remuneration, to execute any and all papers desired by ASSIGNEE, for the filing and granting of foreign applications and the perfecting of title thereto in ASSIGNEE.

AGREED and executed as noted below:

LEGAL NAME OF INVENTOR/JOINT INVENTOR: (E.g., Given Name (first and middle (if any)) and Family Name or Surname)	
Federica Sotgia	
Inventor's Signature: <i>F Sotgia</i>	Date: June 25, 2018

Accepted by assignee Lunella Biotech, Inc.: *Michael P. Lisanti*, dated June 25, 2018
 Michael P. Lisanti, as President of Lunella Biotech, Inc.

We acknowledge the duty to disclose information which is material to the patentability of this application as defined in 37 CFR §1.56.

PATENT